ACR Convergence 2023

November 10-15, 2023. San Diego, CA.

View by Number View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1747

A Newly Described Cytokine interleukin-40 Is Increased in the Serum of Individuals At-risk of Rheumatoid Arthritis and Induces an Inflammatory Response in Mononuclear Cells
Abstract Number: 0798

A Novel 3D Model of Rheumatoid Arthritis Synovial Tissue Incorporating Fibroblasts, Endothelial Cells and Macrophages
Abstract Number: 0866

A Novel 3D-Synovium-Immune Microenvironment Mimics Macrophage-Synovial Fibroblast Interactions in Inflammatory Arthropathies
Abstract Number: 0727

A Novel Active Pemphigus Vulgaris Mouse Model Induced by Immunization with TLR Ligand Adjuvanted Recombinant Desmoglein 3 Protein Vaccine
Abstract Number: 1728

A Novel Animal Model for Investigating the Effect of HLA-DRB1 on Atherosclerosis
Abstract Number: 2534

A Novel Approach for Mixed-methods Research Using Language Learning Models: A Report Using Patients’ Perspectives on Barriers to Hip and Knee Replacement
Abstract Number: 0655

A Novel Association Between Lipodermatosclerosis and Key Vascular Outcomes in Systemic Sclerosis
Abstract Number: 2586

A Novel Blood-Based Assay Differentiates Seropositive and Seronegative Rheumatoid Arthritis from Healthy Individuals and Those with Other Inflammatory Diseases or Osteoarthritis
Abstract Number: 1779

A Novel Inhibitory Pathway of Synovial Inflammation Exerted by Glucocorticoids and TNF Inhibitors Through LAG-3 Up-Regulation
Abstract Number: 0264

A Novel Role for Rheumatologists: Managing Idiopathic Granulomatous Mastitis
Abstract Number: 0940

A Novel Therapeutic Opportunity in Systemic Sclerosis: The Fibrolytic Activities of a Specialized Macrophage Secretome
Abstract Number: 0033

A Novel Transcriptome-Based Machine Learning Pipeline Predicts Phenotypes of Lupus Patients
Abstract Number: 0030

A Pathogenetic Model of IgG4-related Disease Developed from Familial IKZF1 and UBR4 Gene Variants
Abstract Number: 1083

A Patient-Centered Approach to Increase Herpes Zoster Vaccination in Patients on Janus Kinase Inhibitors: A Fellowship Quality Improvement Initiative
Abstract Number: 1654

A Peer Health Coached Resilience-Based Energy Management Program Was Effective in Improving Fatigue and Other Outcomes in People with Systemic Sclerosis: Results of a Randomized Controlled Trial

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].